Physician-Modified Fenestrated Endovascular Aortic Aneurysm Repair After Failed EVAR Offers Promising Results Compared to Open Conversion
Trung Nguyen, Mackenzie Gittinger, Weiwei Liu, Cara L Grzybowski, Shane Grundy, Bruce Zwiebel, Murray Shames, Dean J Arnaoutakis
University of South Florida, Tampa, FL
Background: The incidence of EVAR failure from poor proximal seal, although uncommon, is occurring with greater frequency. Conversion to open repair (EVAR-c) is the gold standard treatment but is associated with significant technical and physiologic challenges. Endovascular salvage by obtaining a more proximal seal zone with a fenestrated/branched endovascular repair (F/BEVAR) is an alternative treatment option. F/BEVAR is limited due to a lack of commercially available custom-made devices and potential overlap issues between the F/BEVAR and the prior EVAR device. Physician-modified F/BEVAR (PM-F/BEVAR) addresses these issues by obtaining the necessary proximal seal and relining the entire prior endograft. However, there is no data directly comparing periprocedural and long-term results of EVAR-c and PM-F/BEVAR. The purpose of this study was to evaluate changes in our practice pattern over time and compare outcomes of EVAR-c and PM-F/BEVAR in patients with failed prior EVAR.
Methods: A prospective database of consecutive patients treated at a single-center with EVAR failure due to poor proximal seal between January 2015 and June 2023 was retrospectively reviewed. All EVAR failures due to infection or thrombosis were excluded (n=56). The cohort was stratified by treatment strategy, either EVAR-c or PM-F/BEVAR. Demographics, operative details, postoperative complications were compared between the groups using univariate analysis. Two-year overall survival was compared using Kaplan-Meier method.
Results: Seventy-six patients underwent treatment of failed EVAR, 41 undergoing EVAR-c and 35 undergoing PM-F/BEVAR. The total number of EVAR-c/year peaked in 2019 (n=11) with the average number EVAR-c/year decreasing by 50% since the inception of a PM-F/BEVAR program in March 2021. Patients who underwent EVAR-c had similar age, gender, and comorbid conditions compared to those who had PM-F/BEVAR (Table I). PM-F/BEVAR patients had more extensive aortic disease, but EVAR-c patients presented more urgently. For EVAR-c patients, crossclamp position was typically supraceliac (n=33[80%]) and crossclamp time was 27±17minutes. For the PM-F/BEVAR group, 132 fenestrations/branches were constructed with an average of 3.8±0.6 target arteries per patient. Fluoroscopy time, radiation dose, contrast use, and technical success were 78±40minutes, 3,103±1,778mGy, 80±25mL, and 100% respectively. Postoperative endoleak was identified in 5 patients (type II: n=4, type Ib: n=1). Blood resource utilization, length of stay, acute renal failure, respiratory complications, and discharge status were significantly better in the PM-F/BEVAR group (Table II). PM-F/BEVAR had significantly decreased 30-day mortality (n=6[15%] vs n=0[0%]; p=.03) but there was no difference in 2-year overall survival (EVAR-c=75% vs PM-F/BEVAR=74%; log-rank p=.73).
Conclusions: Endovascular salvage of failed prior EVAR due to poor proximal seal using a PM-F/BEVAR is safe and effective with significantly better perioperative outcomes compared to EVAR-c. Clinical management of these complex patients has evolved to a predominantly PM-F/BEVAR approach. A PM-F/BEVAR strategy should be strongly considered as first-line therapy in patients with failed EVAR.
| Variable | Total(n=76) | PM-F/BEVAR (n=35) | EVAR-c (n=41) | P-value |
| Male gender | 64 (84) | 30 (86) | 34 (84) | 1.00 |
| Age, years | 75.4 (7.1) | 75.3 (7.4) | 75.6 (7.0) | .85 |
| Coronary artery disease | 42 (55) | 20 (57) | 22 (54) | .82 |
| Congestive heart failure | 6 (8) | 4 (11) | 2 (5) | .41 |
| Hypertension | 73 (96) | 32 (91) | 41 (100) | .09 |
| Body mass index | 26.4 (4.7) | 25.7 (4.9) | 27.0 (4.4) | .20 |
| Chronic renal insufficiencya | 15 (20) | 7 (20) | 8 (20) | 1.00 |
| Chronic pulmonary disease | 28 (37) | 17 (49) | 11 (27) | .06 |
| Moderate-to-severe chronic pulmonary disease | 13 (17) | 9 (26) | 4 (10) | .08 |
| Diabetes mellitus | 12 (16) | 5 (14) | 7 (17) | 1.00 |
| Aneurysm Extent | .06 | |||
| Infrarenal | 5 (7) | 0 (0) | 5 (12) | |
| Juxtarenal | 13 (11) | 3 (9) | 10 (24) | |
| Pararenal | 26 (34) | 13 (37) | 13 (32) | |
| Extent I TAAA | 0 (0) | 0 (0) | 0 (0) | |
| Extent II TAAA | 1 (1) | 1 (3) | 0 (0) | |
| Extent III TAAA | 6 (8) | 3 (9) | 3 (7) | |
| Extent IV TAAA | 24 (32) | 14 (40) | 10 (24) | |
| Extent V TAAA | 1 (1) | 1 (3) | 0 (0) | |
| Max aneurysm diameter, mm | 72.3 (17.0) | 68.2 (14.7) | 75.7 (18.3) | .053 |
| Presentation | .02 | |||
| Elective, intact | 61 (80) | 33 (94) | 28 (68) | |
| Urgent, symptomatic | 7 (9) | 1 (3) | 6 (15) | |
| Emergent, rupture | 8(11) | 1 (3) | 7 (17) |
| Table 2: | Total(n=76) | PM-FEVAR (n=35) | EVAR-c (n=41) | P-value |
| Procedure time, minutes | 246 (90) | 241 (111) | 250 (69) | .67 |
| Spinal drain insertiona | 8 (11) | 8 (23) | 0 (0) | .001 |
| Estimated blood loss | 1,956 (2,244) | 219 (142) | 3,439 (2,127) | <.001 |
| RBC transfusion, # units | 3.4 (4.3) | 0.7 (1.2) | 5.8 (4.6) | <.001 |
| Overall length of stay, days | 10.3 (10.3) | 6.2 (4.0) | 13.9 (12.6) | .001 |
| ICU length of stay, days | 7.7 (10.0) | 4.8 (3.2) | 10.1 (12.8) | .02 |
| Any postoperative complication | 38 (50) | 8 (23) | 30 (73) | <.001 |
| 30-day mortality | 6 (8) | 0 (0) | 6 (15) | .03 |
| Major strokea | 2 (3) | 0 (0) | 2 (5) | .50 |
| Permanent spinal cord ischemia | 1 (1) | 1 (3) | 0 (0) | .72 |
| Acute renal failurec | 28 (37) | 3 (9) | 25 (63) | <.001 |
| Renal replacement therapy | 8 (11) | 1 (3) | 7 (18) | .07 |
| Bowel ischemia | 3 (4) | 0 (0) | 3 (8) | .24 |
| Respiratory complicationd | 15 (20) | 3 (9) | 12 (30) | .02 |
| Discharge to home | 59 (77) | 34 (97) | 25 (60) | .001 |
| 30-day Readmission | 11 (15) | 3 (9) | 11 (15) | .20 |
Back to 2024 Abstracts